menu
PORTFOLIO

GreyBird Portfolio Companies: Hummingbird Diagnostics

The Clinical Problem

Detecting disease from blood suffers from either a lack of specificity (elevated PSA means you “may” have prostate cancer), or a lack of sensitivity in early stages of disease.  New DNA-based liquid biopsies, while accurate, mostly detect cancers after stage 3 when cure rates plummet.

The Hummingbird Solution

Hummingbird Diagnostics, has over 7000 clinical samples tested and 13 granted patents in microRNA diagnostics.  Their carefully engineered methodology has demonstrated sensitivity and specificity of over 90% in early stage cancers and neurodegenerative disorders.

The Business Plan

While already receiving revenues from grants and pharmaceutical trials, the GreyBird investment will fund  large clinical trials in the USA and Europe for early stage lung cancer detection. If the initial results are replicated in the larger trial, it could mean millions of lives saved through early diagnosis.

Latest News from Hummingbird Diagnostics

Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study

READ MORE

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

READ MORE

Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

READ MORE

JÖRG DEBATIN TO CHAIR THE SUPERVISORY BOARD OF HUMMINGBIRD DIAGNOSTICS GMBH International healthcare leader strengthens miRNA experts

READ MORE